Juárez-Navarro Karen J, Padilla-Camberos Eduardo, Díaz Néstor Fabián, Miranda-Altamirano Ariel, Díaz-Martínez N Emmanuel
Biotecnología Médica y Farmacéutica Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Guadalajara, Mexico.
Departamento de Fisiología y Desarrollo Celular, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
Stem Cells Int. 2020 Dec 18;2020:8892189. doi: 10.1155/2020/8892189. eCollection 2020.
Mesenchymal stem cells (MSCs), defined as plastic adherent cells with multipotent differentiation capacity in vitro, are an emerging and valuable tool to treat a plethora of diseases due to their therapeutic mechanisms such as their paracrine activity, mitochondrial and organelle transfer, and transfer of therapeutic molecules via exosomes. Nowadays, there are more than a thousand registered clinical trials related to MSC application around the world, highlighting MSC role on difficult-to-treat high-incidence diseases such as the current COVID-19, HIV infections, and autoimmune and metabolic diseases. Here, we summarize a general overview of MSCs and their therapeutic mechanisms; also, we discuss some of the novel clinical trial protocols and their results as well as a comparison between the number of registries, countries, and search portals.
间充质干细胞(MSCs)被定义为在体外具有多能分化能力的贴壁细胞,由于其治疗机制,如旁分泌活性、线粒体和细胞器转移以及通过外泌体转移治疗分子,它们成为治疗多种疾病的一种新兴且有价值的工具。如今,全球有超过一千项与间充质干细胞应用相关的注册临床试验,凸显了间充质干细胞在治疗诸如当前的新冠病毒病、艾滋病毒感染以及自身免疫性和代谢性疾病等高发性难治疾病中的作用。在此,我们总结了间充质干细胞及其治疗机制的概述;此外,我们还讨论了一些新的临床试验方案及其结果,以及注册数量、国家和搜索平台之间的比较。